Stocks Health care RGEN
NASDAQ · Health careRepligen Corp (RGEN)
Repligen Corp brought in $785.1M of revenue over the twelve months to June 30, 2026, up 16.5% from a year earlier. Net income was $41.5M, a net margin of 5.3%. Operating cash flow minus capital spending left $93.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $606.8M in cash against $551M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.
What Repligen Corp does
Repligen Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $738.3M | $48.9M | $0.86 | $93.9M |
| 2024 | $634.4M | -$25.5M | -$0.46 | $149.7M |
| 2023 | $632.4M | $35.6M | $0.63 | $77.7M |
| 2022 | $801.5M | $186M | $3.24 | $87.2M |
| 2021 | $670.5M | $128.3M | $2.24 | $51.9M |
| 2020 | $366.3M | $59.9M | $1.11 | $40.2M |
Latest SEC filings
What Repligen Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 15, 2026
- September 8, 2026Form 425 filing 425
- September 8, 2026Other event 8-K
- September 4, 2026
- September 4, 2026
- August 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Form 425 filing 425
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- July 29, 2026Quarterly report 10-Q · period to June 30, 2026
Questions about RGEN
What does Repligen Corp do?
Repligen Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGEN.
Is Repligen Corp profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $41.5M on revenue of $785.1M, a net margin of 5.3%.
How much revenue does Repligen Corp make?
Over the twelve months to June 30, 2026 Repligen Corp reported revenue of $785.1M. That is 16.5% more than a year earlier.
When did Repligen Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.
Similar companies
Follow RGEN
Get an email when Repligen Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow RGEN: get an email when it filesWhere the numbers come from
Financial figures are the values Repligen Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.